Bayer is making an aggressive new push to shrink one of the country’s most closely watched mass torts, asking the federal court overseeing Roundup litigation to dismantle nearly 4,000 pending cases after a recent U.S. Supreme Court ruling it says undermines plaintiffs’ core warning-based claims.
The motion targets the federal multidistrict litigation before Judge Vince Chhabria in the Northern District of California, where Roundup plaintiffs have long alleged that Monsanto failed to adequately warn users that the herbicide could cause cancer. Bayer’s position is that the Supreme Court’s June 25 decision significantly strengthens its preemption arguments and weakens the legal foundation for failure-to-warn theories in federal court.
If Judge Chhabria agrees, the ruling could dramatically alter the trajectory of the MDL, which has served as a central forum for coordinated discovery, bellwether preparation, and settlement pressure. Recent federal filings in the court include cases such as Willis v. Monsanto Co and Phelps v. Monsanto Company, both of which sit against the backdrop of Bayer’s broader effort to narrow or defeat federal claims at the pleading or dispositive-motion stage.
For litigators, the immediate significance is procedural as much as substantive. A successful preemption-based challenge in the MDL would not simply trim a few cases; it could reset settlement leverage, affect expert strategy, and reshape how plaintiffs frame claims going forward. Defense counsel in other regulated-products cases will also be watching closely for how broadly the court reads the Supreme Court’s reasoning and whether it can be used to foreclose state-law warning claims where federal labeling regimes are involved.
For in-house counsel and compliance teams, the case is a reminder that Supreme Court developments can quickly cascade into enterprise-level litigation strategy. A favorable ruling for Bayer in federal court could reduce exposure in one major forum while leaving state-court inventories as a separate and still-dangerous front. That split matters: companies facing coordinated product-liability dockets often have to manage inconsistent risk across jurisdictions, even when a federal preemption argument gains traction.
The key question now is whether the federal court sees the Supreme Court’s decision as decisive enough to justify broad dismissal, or whether plaintiffs can preserve claims by distinguishing the ruling or reframing their theories. Either way, the next phase of the Roundup fight will be important reading for anyone tracking the intersection of preemption doctrine, MDL practice, and nationwide mass-tort risk.